RxDoctor Payments Data

Spencer Lee, MD

Pulmonary Disease · Canton, GANPI 1831415157

Payments from drug & device makers

$8,215in general payments, 2019–2025

Across 256 payments — averaging $32.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$4K
  • GSK$855
  • Boehringer Ingelheim$411
  • Sanofi$381
  • AstraZeneca$363
  • Actelion Pharmaceuticals US, Inc.$351
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$5,02561%
  • Education$3,19039%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,215 in reported general payments places this provider in the 60th percentile of 365 pulmonary disease providers in Georgia.

See all pulmonary disease providers in Georgia

Medicare billing

Part B allowed, 2024
$141,151
Medicare patients
443
Services billed
1,313

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UptraviSelexipag24$268,773
Trelegy ElliptaFluticasone/Umeclidin/Vilanter265$218,185
OpsumitMacitentan12$154,652
Prolastin CAlpha-1-Proteinase Inhibitor11$107,597
Dupixent PenDupilumab18$73,219
Breztri AerosphereBudesonide/Glycopyr/Formoterol66$51,188
Dupixent SyringeDupilumab13$48,067
EliquisApixaban51$32,995
Breo ElliptaFluticasone/Vilanterol38$20,437
Spiriva RespimatTiotropium Bromide21$20,028
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr27$13,848
Stiolto RespimatTiotropium Br/Olodaterol Hcl14$9,404
Advair HfaFluticasone Propion/Salmeterol11$5,803
SymbicortBudesonide/Formoterol Fumarate21$4,949
BelsomraSuvorexant11$4,725

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit$351$423,42536 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$855$252,470330 claims
Grifols USA, LLCProlastin C$219$107,59711 claims
AstraZenecaBreztri Aerosphere, Symbicort$363$56,13787 claims
PfizerEliquis$126$32,99551 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$411$29,43235 claims
MerckBelsomra$55$4,72511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 365 pulmonary disease providers in Georgia.

Other pulmonary disease in Canton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →